People with relapsed small cell #lungcancer need more treatment options.
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
July 26, 2026 at 9:40 PM
People with relapsed small cell #lungcancer need more treatment options.
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
🆕 early study of targeted ADC izalontamab brengitecan reports encouraging results. Treatment is designed to target EGFR & HER3, with HER3 also emerging as a potential biomarker for response.
ascopubs.org/doi/full/10.... #LCSM
#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
January 28, 2026 at 5:38 AM
#Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with #EGFR-mutated #NSCLC: Pooled analysis of phase 1 and phase 2 trials
www.annalsofoncology.org/article/S092...
www.annalsofoncology.org/article/S092...
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
July 19, 2026 at 10:00 AM
Long-term single-molecule tracking reveals EGFR, HER2, and HER3 dimerization dynamics. Oncogenic mutations stabilize dimerization, impacting signaling. Insights offer new paths for targeted therapies. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate - OncoDaily
Iza-Bren is an EGFR×HER3 bispecific ADC showing significant clinical activity and regulatory momentum in EGFR-driven solid tumors.
oncodaily.com
January 12, 2026 at 1:05 AM
Iza-Bren (EGFR×HER3 ADC): A Next-Generation Dual-Targeted Antibody–Drug Conjugate
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
oncodaily.com/drugs/iza-br...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #ADC
Study reveals long-term tracking of EGFR, HER2, and HER3 shows oncogenic mutations lead to stable dimerization, disrupting normal activation dynamics. 3 receptors, 1 technique! PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA #ASHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
August 13, 2026 at 9:00 PM
Long-term SPT of EGFR, HER2, and HER3 reveals oncogenic EGFR mutations induce stable, ligand-independent dimerization, impacting ErbB signaling dynamics significantly. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
September 12, 2026 at 11:00 PM
Interesting data on DB-1310 a new HER3 ADC, presented by Lisberg with good responses in all solid tumors as well as EGFR mut lung #ASCO25 (just after Merck pulled their BLA for patritumab, another HER3 ADC in EGFR mut lung)
May 30, 2025 at 8:00 PM
Interesting data on DB-1310 a new HER3 ADC, presented by Lisberg with good responses in all solid tumors as well as EGFR mut lung #ASCO25 (just after Merck pulled their BLA for patritumab, another HER3 ADC in EGFR mut lung)
Data on iza-bren (BL-B01D1) an EGFR/HER3 ADC in patients with Small Cell and NSCLC (a variety of driver alterations). Fair response rate in all types of lung cancer (conf RR 48% in small cell) #ASCO25
May 30, 2025 at 8:19 PM
Data on iza-bren (BL-B01D1) an EGFR/HER3 ADC in patients with Small Cell and NSCLC (a variety of driver alterations). Fair response rate in all types of lung cancer (conf RR 48% in small cell) #ASCO25
#ASCO25
Drug development track 🔥
IZA-BREN/BL-B01D1
💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths
✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!
#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social
Drug development track 🔥
IZA-BREN/BL-B01D1
💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths
✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!
#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social
May 30, 2025 at 8:29 PM
#ASCO25
Drug development track 🔥
IZA-BREN/BL-B01D1
💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths
✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!
#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social
Drug development track 🔥
IZA-BREN/BL-B01D1
💉 EGFR-HER3 bispecific ADC (TOP I) #NSCLC
☣️ Hematological
☣️ 1 ILD G2, no deaths
✅ORR 45.6%
✅ Exon 20ins: 85%, HERm: 61.5%
✅ SCLC ORR 75%!
#OncoNexion25 @oncoalert.bsky.social
@myesmo.bsky.social @ascocancer.bsky.social
@vhio.bsky.social
İkili tedavi, preklinik akciğer kanseri modellerinde yaşam süresini uzatıyor.
HER3-DXd ve Olaparib, EGFR veya KRAS mutasyonları olan tümörlerde birlikte etkili oldu.
HER3-DXd ve Olaparib, EGFR veya KRAS mutasyonları olan tümörlerde birlikte etkili oldu.
August 26, 2026 at 3:47 PM
İkili tedavi, preklinik akciğer kanseri modellerinde yaşam süresini uzatıyor.
HER3-DXd ve Olaparib, EGFR veya KRAS mutasyonları olan tümörlerde birlikte etkili oldu.
HER3-DXd ve Olaparib, EGFR veya KRAS mutasyonları olan tümörlerde birlikte etkili oldu.
Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in adva...
bit.ly
December 13, 2024 at 10:24 AM
Innovative therapies in GU cancers: Promising targets in #Urothelial and #Kidney cancer.- BL-B01D1: A bispecific ADC (EGFR/HER3) with a 40% response rate in advanced urothelial cancer.
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
- NKT2152: A HIF2a inhibitor for RCC, showing promise but with toxicity challenges > bit.ly/3OUcvfe
Phase 1b trial: BL-B01D1, an EGFR-HER3 bispecific ADC with a topoisomerase I inhibitor, shows promising efficacy/safety in 82 advanced ESCC patients. PMID:40640393, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03792-7 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial | Nature Medicine
Research on patients with advanced esophageal squamous cell carcinoma (ESCC) who have progressed on immunotherapy remains limited. BL-B01D1 is a first-in-class antibody–drug conjugate consisting of an EGFR–HER3 bispecific antibody bound to a topoisomerase I inhibitor (Ed-04) payload via a cleavable linker. Here, we present safety and efficacy data from a phase 1 study of BL-B01D1, in 82 patients previously treated for ESCC. The primary endpoint was the recommended phase 2 dose. Administered doses were 2.0 (n = 22) and 2.5 (n = 60) mg kg−1 D1D8 infusion every 3 weeks (Q3W). The confirmed objective response rate (cORR) was 29.3% (24 of 82) in all patients and 32.9% (24 of 73) among evaluable patients. For patients dosed at 2.5 mg kg−1, cORR was 39.6% (21 of 53) and disease control rate was 79.2% (42 of 53). In the 2.0 mg kg−1 group, cORR was 15.0% (3 of 20), and the disease control rate was 50.0% (10 of 20). The phase 2 dose was established at 2.5 mg kg−1 D1D8 Q3W. The incidence of G3 tr
doi.org
August 29, 2025 at 4:10 AM
Phase 1b trial: BL-B01D1, an EGFR-HER3 bispecific ADC with a topoisomerase I inhibitor, shows promising efficacy/safety in 82 advanced ESCC patients. PMID:40640393, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03792-7 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Can one bispecific ADC actually work across three biologically distinct breast cancer subtypes?
www.annalsofoncology.org/article/S092...
Safety & antitumor activity of the first-in-class EGFR–HER3 bispecific ADC iza-bren (BL-B01D1) in patients with pretreated locally Adv/ metastatic breast cancer
www.annalsofoncology.org/article/S092...
Safety & antitumor activity of the first-in-class EGFR–HER3 bispecific ADC iza-bren (BL-B01D1) in patients with pretreated locally Adv/ metastatic breast cancer
September 15, 2026 at 10:09 AM
Can one bispecific ADC actually work across three biologically distinct breast cancer subtypes?
www.annalsofoncology.org/article/S092...
Safety & antitumor activity of the first-in-class EGFR–HER3 bispecific ADC iza-bren (BL-B01D1) in patients with pretreated locally Adv/ metastatic breast cancer
www.annalsofoncology.org/article/S092...
Safety & antitumor activity of the first-in-class EGFR–HER3 bispecific ADC iza-bren (BL-B01D1) in patients with pretreated locally Adv/ metastatic breast cancer
Bir Faz 1 çalışması, EGFR mutasyonlu akciğer kanserinde deneysel EGFR x HER3 antikor-aktif madde konjugatı için önerilen Faz 3 dozunu destekledi.
September 13, 2026 at 11:24 AM
Bir Faz 1 çalışması, EGFR mutasyonlu akciğer kanserinde deneysel EGFR x HER3 antikor-aktif madde konjugatı için önerilen Faz 3 dozunu destekledi.
Track the dimerization dynamics of EGFR, HER2, and HER3 in live cells! Long-term SPT reveals that oncogenic EGFR mutations stabilize dimers independently of ligands, reshaping receptor interactions. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5
No description available
www.cell.com
September 1, 2026 at 3:00 AM
Track the dimerization dynamics of EGFR, HER2, and HER3 in live cells! Long-term SPT reveals that oncogenic EGFR mutations stabilize dimers independently of ligands, reshaping receptor interactions. PMID:42054992, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00399-5 #Medsky 🧪
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. www.thelancet.com/journals/lan...
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, ope...
Iza-bren significantly improved the ORR compared with chemotherapy in individuals
with heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, with a manageable
safety profile. These find...
www.thelancet.com
October 23, 2025 at 1:23 PM
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. www.thelancet.com/journals/lan...
"A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
www.nature.com
July 10, 2025 at 12:01 PM
"A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial"
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
#Caregiving #Health="/hashtag/Healthcare" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Healthcare #ElderCare #MedSky
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. www.annalsofoncology.org/article/S092...
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
Therapeutic options after progression on EGFR tyrosine kinase inhibitors (TKIs) remain
limited for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Izalontamab
brengitecan (Iza-bren; BL-...
www.annalsofoncology.org
January 29, 2026 at 12:49 PM
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials. www.annalsofoncology.org/article/S092...
HER3-DXd demonstrated some activity in a phase 3 trial of patients with previously treated, EGFR-mutant #NSCLC, but a lack of OS benefit prompted the withdrawal of the BLA for the antibody-drug conjugate. From @cancertherapyadv.bsky.social.
bit.ly/4lcoPpO
#lcsm
bit.ly/4lcoPpO
#lcsm
HER3-DXd Falls Short in NSCLC Trial, Prompting BLA Withdrawal - Oncology Nurse Advisor
HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.
bit.ly
July 15, 2025 at 3:15 PM
HER3-DXd demonstrated some activity in a phase 3 trial of patients with previously treated, EGFR-mutant #NSCLC, but a lack of OS benefit prompted the withdrawal of the BLA for the antibody-drug conjugate. From @cancertherapyadv.bsky.social.
bit.ly/4lcoPpO
#lcsm
bit.ly/4lcoPpO
#lcsm
RRIDs were included in this in Journal of Clinical Investigation paper. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #BetterScience #accelerateopenscience
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer
Read the full paper: EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer
doi.org
June 7, 2026 at 7:03 AM
RRIDs were included in this in Journal of Clinical Investigation paper. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #BetterScience #accelerateopenscience
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - "Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond"
academic.oup.com/abt/article/...
#bsAb #ADC #HER3 #c-Met
academic.oup.com/abt/article/...
#bsAb #ADC #HER3 #c-Met
Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond
Statement of Significance We developed SDP0505, a first-in-class HER3/c-Met bispecific ADC, based on prevalent co-expression of both targets in numerous ca
academic.oup.com
July 13, 2026 at 12:44 PM
Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - "Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond"
academic.oup.com/abt/article/...
#bsAb #ADC #HER3 #c-Met
academic.oup.com/abt/article/...
#bsAb #ADC #HER3 #c-Met
A dual therapy outperformed either drug alone in lung cancer models, driving DNA damage beyond repair and activating immune defenses. The effect appeared in both EGFR- and KRAS-mutant tumors. doi.org/hcgnpm
Dual therapy activates immune defenses while damaging lung cancer DNA
A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models.
medicalxpress.com
August 24, 2026 at 4:20 PM
A dual therapy outperformed either drug alone in lung cancer models, driving DNA damage beyond repair and activating immune defenses. The effect appeared in both EGFR- and KRAS-mutant tumors. doi.org/hcgnpm
RRID:Addgene_116722, was just reported to be used in "GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells". RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #reproducibility
doi.org
March 6, 2025 at 8:01 AM
RRID:Addgene_116722, was just reported to be used in "GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells". RRIDs like this improve reproducibility in scientific research. #ReproducibleResearch #reproducibility
📍Resistance Solutions
☑️ HER3-DXd ADC shows promise post-TKI resistance (ORR 30%).
☑️ Fourth-gen TKIs (BDTX-1535) target C797S mutations in trials.
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
☑️ HER3-DXd ADC shows promise post-TKI resistance (ORR 30%).
☑️ Fourth-gen TKIs (BDTX-1535) target C797S mutations in trials.
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
March 20, 2025 at 7:31 PM
📍Resistance Solutions
☑️ HER3-DXd ADC shows promise post-TKI resistance (ORR 30%).
☑️ Fourth-gen TKIs (BDTX-1535) target C797S mutations in trials.
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials
☑️ HER3-DXd ADC shows promise post-TKI resistance (ORR 30%).
☑️ Fourth-gen TKIs (BDTX-1535) target C797S mutations in trials.
#Onco404 #Oncology #Cancer #LungCancer #PrecisionMedicine #PrecisionOncology #EGFR #ClinicalTrials